Shares of Balchem Co. (NASDAQ:BCPC - Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $161.03, but opened at $156.36. Balchem shares last traded at $161.16, with a volume of 8,186 shares.
Analysts Set New Price Targets
Several analysts recently issued reports on BCPC shares. StockNews.com raised shares of Balchem from a "hold" rating to a "buy" rating in a report on Monday, October 28th. HC Wainwright upped their target price on shares of Balchem from $185.00 to $190.00 and gave the company a "buy" rating in a research note on Monday, November 4th.
View Our Latest Report on Balchem
Balchem Trading Down 0.6 %
The company has a quick ratio of 1.90, a current ratio of 2.98 and a debt-to-equity ratio of 0.21. The firm's 50 day moving average is $168.26 and its two-hundred day moving average is $170.87. The stock has a market cap of $5.21 billion, a price-to-earnings ratio of 42.92, a price-to-earnings-growth ratio of 4.36 and a beta of 0.69.
Balchem Increases Dividend
The company also recently announced an annual dividend, which was paid on Friday, January 17th. Shareholders of record on Thursday, December 26th were paid a dividend of $0.87 per share. This represents a yield of 0.4%. This is a positive change from Balchem's previous annual dividend of $0.79. The ex-dividend date of this dividend was Thursday, December 26th. Balchem's payout ratio is presently 23.39%.
Institutional Investors Weigh In On Balchem
A number of hedge funds have recently made changes to their positions in the business. Westside Investment Management Inc. bought a new stake in Balchem during the 3rd quarter valued at $27,000. R Squared Ltd acquired a new stake in Balchem in the fourth quarter worth about $29,000. nVerses Capital LLC bought a new position in Balchem in the 3rd quarter valued at about $35,000. Wilmington Savings Fund Society FSB acquired a new position in Balchem during the 3rd quarter valued at about $35,000. Finally, GAMMA Investing LLC raised its position in shares of Balchem by 73.4% during the 3rd quarter. GAMMA Investing LLC now owns 841 shares of the basic materials company's stock worth $148,000 after buying an additional 356 shares in the last quarter. Institutional investors own 87.91% of the company's stock.
Balchem Company Profile
(
Get Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
